Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	24208	vascula$10 near3 (permeab$8 or leak$6) or edema$	US-PGPUB; USPAT	OR	OFF	2005/08/09 10:12
L2	12413	src	US-PGPUB; USPAT	OR	OFF	2005/08/09 10:13
L3	38	1 same 2	US-PGPUB; USPAT	OR	OFF	2005/08/09 10:13
L4	1200	2 near10 (inhibit$8 or decreas$8)	US-PGPUB; USPAT	OR	OFF	2005/08/09 10:25
L5	164	1 and 4	US-PGPUB; USPAT	OR	OFF	2005/08/09 10:25

3/29/06

```
  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:16:39 ON 09 AUG 2005

=> fil .bec
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
       ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 11:16:51 ON 09 AUG 2005
ALL COPYRIGHTS AND RESTRICTIONS APPLY.  SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s vascula?(3a)(permeab? or leak?) or edema?
FILE 'MEDLINE'
        377870 VASCULA?
         99161 PERMEAB?
         40828 LEAK?
          7534 VASCULA?(3A)(PERMEAB? OR LEAK?)
         81762 EDEMA?
L1       87886 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'SCISEARCH'
        238013 VASCULA?
        107218 PERMEAB?
         53800 LEAK?
          8557 VASCULA?(3A)(PERMEAB? OR LEAK?)
         38623 EDEMA?
L2       45885 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'LIFESCI'
         25385 VASCULA?
         18131 PERMEAB?
          5687 LEAK?
          1231 VASCULA?(3A)(PERMEAB? OR LEAK?)
          4426 EDEMA?
L3        5488 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOTECHDS'
          4388 VASCULA?
          3346 PERMEAB?
          1010 LEAK?
           142 VASCULA?(3A)(PERMEAB? OR LEAK?)
           372 EDEMA?
L4         501 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOSIS'
       2176595 VASCULA?
         95570 PERMEAB?
         35473 LEAK?
          9299 VASCULA?(3A)(PERMEAB? OR LEAK?)
         59036 EDEMA?
L5       66709 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'EMBASE'
        379562 VASCULA?
         84610 PERMEAB?
         37526 LEAK?
          6974 VASCULA?(3A)(PERMEAB? OR LEAK?)
         86100 EDEMA?
L6       91599 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?
```

```
FILE 'HCAPLUS'
        153048 VASCULA?
        212758 PERMEAB?
         88247 LEAK?
          6802 VASCULA?(3A)(PERMEAB? OR LEAK?)
         31053 EDEMA?
L7       36638 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'NTIS'
          2551 VASCULA?
         12986 PERMEAB?
         15104 LEAK?
            94 VASCULA?(3A)(PERMEAB? OR LEAK?)
           803 EDEMA?
L8          880 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'ESBIOBASE'
         75800 VASCULA?
         54330 PERMEAB?
         10529 LEAK?
          2372 VASCULA?(3A)(PERMEAB? OR LEAK?)
          7737 EDEMA?
L9        9776 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'BIOTECHNO'
         33459 VASCULA?
         18106 PERMEAB?
          4574 LEAK?
          1268 VASCULA?(3A)(PERMEAB? OR LEAK?)
          3864 EDEMA?
L10       4950 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

FILE 'WPIDS'
         23624 VASCULA?
        113129 PERMEAB?
        149364 LEAK?
           501 VASCULA?(3A)(PERMEAB? OR LEAK?)
          2903 EDEMA?
L11       3332 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

TOTAL FOR ALL FILES
L12     353644 VASCULA?(3A)(PERMEAB? OR LEAK?) OR EDEMA?

=> s src
FILE 'MEDLINE'
L13       16220 SRC

FILE 'SCISEARCH'
L14       15142 SRC

FILE 'LIFESCI'
L15        5826 SRC

FILE 'BIOTECHDS'
L16         318 SRC

FILE 'BIOSIS'
L17       15137 SRC

FILE 'EMBASE'
L18       11671 SRC

FILE 'HCAPLUS'
L19       15623 SRC
```

```
FILE 'NTIS'
L20        2030 SRC

FILE 'ESBIOBASE'
L21        8142 SRC

FILE 'BIOTECHNO'
L22        7046 SRC

FILE 'WPIDS'
L23         976 SRC

TOTAL FOR ALL FILES
L24       98131 SRC

=> s l12 and l24
FILE 'MEDLINE'
L25          43 L1 AND L13

FILE 'SCISEARCH'
L26          54 L2 AND L14

FILE 'LIFESCI'
L27          11 L3 AND L15

FILE 'BIOTECHDS'
L28           3 L4 AND L16

FILE 'BIOSIS'
L29          50 L5 AND L17

FILE 'EMBASE'
L30          34 L6 AND L18

FILE 'HCAPLUS'
L31          71 L7 AND L19

FILE 'NTIS'
L32           1 L8 AND L20

FILE 'ESBIOBASE'
L33          26 L9 AND L21

FILE 'BIOTECHNO'
L34           9 L10 AND L22

FILE 'WPIDS'
L35          39 L11 AND L23

TOTAL FOR ALL FILES
L36         341 L12 AND L24

=> dup rem 136
PROCESSING COMPLETED FOR L36
L37          153 DUP REM L36 (188 DUPLICATES REMOVED)

=> d 1-30

L37   ANSWER 1 OF 153  BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
TI    Use of pasireotide in manufacturing a medicament for treating disorders
      of growth regulation, acromegaly, diabetes, obesity, Grave's disease,
      macular edema, cancer and sleep apnea in a selected patient
      population;
```

pasirotide and gene expression profiling for use in disease therapy
AU SAULNIER M
AN 2005-19896 BIOTECHDS
PI WO 2005053732 16 Jun 2005

L37 ANSWER 2 OF 153 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
TI Preparation of imidazol[1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases
SO Jpn. Kokai Tokkyo Koho, 75 pp.
CODEN: JKXXAF
IN Mukoyama, Harunobu; Nishimura, Toshihiro; Nakayama, Akiko; Kikuchi, Shinji; Komatsu, Yoshimitsu; Onoda, Hideki
AN 2005:299462 HCAPLUS
DN 142:355287

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005089352	A2	20050407	JP 2003-323350	20030916

L37 ANSWER 3 OF 153 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
TI Pyrazolo[1,5-a]pyrimidine derivatives, prophylactic or therapeutic agents containing them for protein tyrosine kinase-related diseases, and combination drugs containing them
SO Jpn. Kokai Tokkyo Koho, 80 pp.
CODEN: JKXXAF
IN Mukoyama, Harunobu; Shiohara, Hiroaki; Nishimura, Toshihiro; Nakayama, Akiko; Kikuchi, Shinji; Komatsu, Yoshimitsu; Onoda, Hideki
AN 2005:33492 HCAPLUS
DN 142:127563

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005008581	A2	20050113	JP 2003-175930	20030620

L37 ANSWER 4 OF 153 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI New thieno/furo-pyridine derivatives are protein tyrosine kinase inhibitors useful for treatment of e.g. ocular disorders, cardiovascular disorders, cancer.
PI WO 2005010009 A1 20050203 (200515)* EN 391 C07D495-04
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
US 2005026944 A1 20050203 (200515) C07D491-02
IN BETSCHMANN, P; BURCHAT, A F; CALDERWOOD, D J; CURTIN, M L; DAVIDSEN, S K; DAVIS, H M; FREY, R R; HEYMAN, H R; HIRST, G C; HRNCIAR, P; MICHAELIDES, M R; MUCKEY, M A; RAFFERTY, P; WADA, C K

L37 ANSWER 5 OF 153 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI New pyrrole pyridine derivatives are protein tyrosine kinase inhibitors useful to treat e.g. cancers, ocular conditions, cardiovascular conditions, chronic inflammation, systemic lupus, psoriasis, Paget's disease, stroke and endometriosis.
PI US 2005043347 A1 20050224 (200520)* 181 C07D491-02
IN BETSCHMANN, P; BURCHAT, A F; CALDERWOOD, D J; CURTIN, M L; DAVIDSEN, S K; DAVIS, H M; FREY, R R; HEYMAN, H R; HIRST, G C; HRNCIAR, P; MICHAELIDES, M R; MUCKEY, M A; RAFFERTY, P; WADA, C K

L37 ANSWER 6 OF 153 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI New thienopyridine derivatives are protein kinase inhibitors, useful for treating e.g. cancer, ocular condition, cardiovascular condition, diabetic condition, sickle cell anemia and inflammatory bowel disease.

PI US 2005020619 A1 20050127 (200513)* 76 C07D498-02
IN BETSCHMANN, P; BURCHAT, A; CALDERWOOD, D; CURTIN, M L; DAVIDSEN, S K; DAVIS, H M; FREY, R R; HEYMAN, H R; HIRST, G; HRNCIAR, P; MICHAELIDES, M; RAFFERTY, P

L37 ANSWER 7 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI HIF-1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates **Src**-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
SO ONCOGENE, (28 APR 2005) Vol. 24, No. 19, pp. 3110-3120. ISSN: 0950-9232.
AU Gray M J; Zhang J; Ellis L M; Semenza G L; Evans D B; Watowich S S; Gallick G E (Reprint)
AN 2005:472725 SCISEARCH

L37 ANSWER 8 OF 153 MEDLINE on STN DUPLICATE 4
TI Tumor metastasis but not tumor growth is dependent on **Src** -mediated **vascular permeability.**
SO Blood, (2005 Feb 15) 105 (4) 1508-14. Electronic Publication: 2004-10-14. Journal code: 7603509. ISSN: 0006-4971.
AU Criscuoli Michele L; Nguyen Mai; Eliceiri Brian P
AN 2005060850 MEDLINE

L37 ANSWER 9 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis
SO JOURNAL OF CELL BIOLOGY, (20 JUN 2005) Vol. 169, No. 6, pp. 941-952. ISSN: 0021-9525.
AU Shen T L; Park A Y J; Alcaraz A; Peng X; Jang I; Koni P; Flavell R A; Gu H; Guan J L (Reprint)
AN 2005:663724 SCISEARCH

L37 ANSWER 10 OF 153 MEDLINE on STN DUPLICATE 5
TI Inhibition of the **Src** and Jak Kinases Protects against Lipopolysaccharide-induced Acute Lung Injury.
SO American journal of respiratory and critical care medicine, (2005 Apr 15) 171 (8) 858-67. Electronic Publication: 2005-01-21. Journal code: 9421642. ISSN: 1073-449X.
AU Severgnini Mariano; Takahashi Satoe; Tu Powen; Perides George; Homer Robert J; Jhung Jhung W; Bhavsar Deepa; Cochran Brent H; Simon Amy R
AN 2005184113 IN-PROCESS

L37 ANSWER 11 OF 153 MEDLINE on STN DUPLICATE 6
TI Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues.
SO Circulation research, (2005 Feb 18) 96 (3) 384-91. Electronic Publication: 2005-01-20. Journal code: 0047103. ISSN: 1524-4571.
AU Lambeng Nathalie; Wallez Yann; Rampon Christine; Cand Francine; Christe Georges; Gulino-Debrac Danielle; Vilgrain Isabelle; Huber Philippe
AN 2005088277 MEDLINE

L37 ANSWER 12 OF 153 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Molecularly targeted therapy for gastrointestinal cancer.
SO Current Cancer Drug Targets, (2005) Vol. 5, No. 3, pp. 171-193. Refs: 102 ISSN: 1568-0096 CODEN: CCDTB
AU Wiedmann M.W.; Caca K.
AN 2005226075 EMBASE

L37 ANSWER 13 OF 153 MEDLINE on STN DUPLICATE 7

TI Modulation of peripheral inflammation in sensory ganglia by nuclear factor (kappa)B decoy oligodeoxynucleotide: involvement of **SRC** kinase pathway.
SO Neuroscience letters, (2005 Jun 10-17) 381 (1-2) 114-9. Electronic Publication: 2005-02-25.
Journal code: 7600130. ISSN: 0304-3940.
AU Igwe Orisa J
AN 2005245223 IN-PROCESS

L37 ANSWER 14 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Comparison of the signaling mechanisms by which VEGF, H2O2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase
SO MICROVASCULAR RESEARCH, (JAN 2005) Vol. 69, No. 1-2, pp. 36-44.
ISSN: 0026-2862.
AU Tao Q; Spring S C; Terman B I (Reprint)
AN 2005:428794 SCISEARCH

L37 ANSWER 15 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI 17 beta-estradiol transiently disrupts adherens junctions in endothelial cells
SO FASEB JOURNAL, (MAY 2005) Vol. 19, No. 7.
ISSN: 0892-6638.
AU Groten T (Reprint); Pierce A A; Huen A C; Schnaper H W
AN 2005:613823 SCISEARCH

L37 ANSWER 16 OF 153 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
TI Composition for treating or preventing a blood-brain barrier disorder, e.g. multiple sclerosis, ischemia, Alzheimer's disease, brain tumors, or hypertension, comprises an **src**-suppressed C kinase substrate protein;
involving vector-mediated gene transfer and expression in host cell for therapy
AU KIM K; LEE S; KIM W
AN 2005-03352 BIOTECHDS
PI WO 2004110476 23 Dec 2004

L37 ANSWER 17 OF 153 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 9
TI Methods and compositions useful for modulation of angiogenesis and **vascular permeability** using **SRC** or Yes tyrosine kinases.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Feb 3 2004) Vol. 1279, No. 1. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).
AU Cheresh, David A. [Inventor, Reprint Author]; Eliceiri, Brian [Inventor]
AN 2004:130012 BIOSIS

L37 ANSWER 18 OF 153 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 10
TI Preparation of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles as **Src** inhibitors for the treatment of ischemic injury
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
IN Boschelli, Diane Harris; Zaleska, Margaret Maria; Boschelli, Frank Charles; Arndt, Kim Timothy
AN 2004:740166 HCAPLUS
DN 141:243354

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004075898	A1	20040910	WO 2004-US4904	20040219

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,

BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
MZ, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 2004229880	A1	20041118	US 2004-780973	20040218

L37 ANSWER 19 OF 153 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 11
TI Inhibition of **src** family kinases for the treatment of reperfusion injury related to revascularization
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
IN Losordo, Douglas W.
AN 2004:331894 HCAPLUS
DN 140:350577

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004032709	A2	20040422	WO 2003-US31430	20031003
WO 2004032709	A3	20041007		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500368	AA	20040422	CA 2003-2500368	20031003

L37 ANSWER 20 OF 153 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 12
TI Preparation of vasculostatic agents and methods of use
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
IN Wrasidlo, Wolfgang; Doukas, John; Royston, Ivor; Noronha, Glenn; Hood, John D.; Dneprovskaia, Elena; Gong, Xianchang; Splittgerber, Ute; Zhao, Ningning
AN 2004:308364 HCAPLUS
DN 140:321386

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004030635	A2	20040415	WO 2003-US31721	20031002
WO 2004030635	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500727	AA	20040415	CA 2003-2500727	20031002
US 2004167198	A1	20040826	US 2003-679209	20031002
EP 1549614	A2	20050706	EP 2003-774610	20031002

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

L37 ANSWER 21 OF 153 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI New pyrrolotriazine derivatives useful for treatment of proliferative disease e.g. cancer, inflammation and autoimmune disease.
PI WO 2004013145 A1 20040212 (200420)* EN 71 C07D487-04
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
US 2004063708 A1 20040401 (200425) A61K031-53
AU 2003265349 A1 20040223 (200453) C07D487-04
EP 1543009 A1 20050622 (200541) EN C07D487-04
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
IN BHIDE, R S; BORZILLERI, R M

L37 ANSWER 22 OF 153 LIFESCI COPYRIGHT 2005 CSA on STN
TI Activation of Vascular Endothelial Growth Factor Receptor-3 and Its Downstream Signaling Promote Cell Survival under Oxidative Stress
SO Journal of Biological Chemistry [J. Biol. Chem.], (20040625) vol. 279, no. 26, pp. 27088-27097.
ISSN: 0021-9258.
AU Wang, J.F.; Zhang, X.; Groopman, J.E.
AN 2004:85045 LIFESCI

L37 ANSWER 23 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Angiogenesis and its role in the behavior of astrocytic brain tumors
SO FRONTIERS IN BIOSCIENCE, (1 SEP 2004) Vol. 9, Supp. [S], pp. 3105-3123.
ISSN: 1093-9946.
AU Stiver S I (Reprint)
AN 2004:819609 SCISEARCH

L37 ANSWER 24 OF 153 MEDLINE on STN DUPLICATE 13
TI **Src** family kinase inhibitor PP1 reduces secondary damage after spinal cord compression in rats.
SO Journal of neurotrauma, (2004 Jul) 21 (7) 923-31.
Journal code: 8811626. ISSN: 0897-7151.
AU Akiyama Chihiro; Yuguchi Takamichi; Nishio Masami; Tomishima Takahiro; Fujinaka Toshiyuki; Taniguchi Masaaki; Nakajima Yoshikazu; Kohmura Eiji; Yoshimine Toshiki
AN 2004404797 MEDLINE

L37 ANSWER 25 OF 153 MEDLINE on STN DUPLICATE 14
TI Signaling pathways for early brain injury after subarachnoid hemorrhage.
SO Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, (2004 Aug) 24 (8) 916-25.
Journal code: 8112566. ISSN: 0271-678X.
AU Kusaka Gen; Ishikawa Mami; Nanda Anil; Granger D Neil; Zhang John H
AN 2004454757 MEDLINE

L37 ANSWER 26 OF 153 MEDLINE on STN DUPLICATE 15
TI **Src** blockade stabilizes a Flk/cadherin complex, reducing **edema** and tissue injury following myocardial infarction.
SO Journal of clinical investigation, (2004 Mar) 113 (6) 885-94.
Journal code: 7802877. ISSN: 0021-9738.
AU Weis Sara; Shintani Satoshi; Weber Alberto; Kirchmair Rudolf; Wood Malcolm; Cravens Adrianna; McSharry Heather; Iwakura Atsushi; Yoon Young-Sup; Himes Nathan; Burstein Deborah; Doukas John; Soll Richard;

Losordo Douglas; Cheresh David
AN 2004172915 MEDLINE

L37 ANSWER 27 OF 153 MEDLINE on STN DUPLICATE 16
TI Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction.
SO Journal of molecular and cellular cardiology, (2004 Apr) 36 (4) 547-59. Journal code: 0262322. ISSN: 0022-2828.
AU Fukuda Shoji; Kaga Shigeaki; Sasaki Hiroaki; Zhan Lijun; Zhu Li; Otani Hajime; Kalfin Reni; Das Dipak K; Maulik Nilanjana
AN 2004186500 MEDLINE

L37 ANSWER 28 OF 153 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Matrix-specific activation of **Src** and Rho initiates capillary morphogenesis of endothelial cells
SO FASEB JOURNAL, (MAR 2004) Vol. 18, No. 3, pp. 457-468. ISSN: 0892-6638.
AU Liu Y Q; Senger D R (Reprint)
AN 2004:311780 SCISEARCH

L37 ANSWER 29 OF 153 MEDLINE on STN DUPLICATE 17
TI Influenza virus inhibits ENaC and lung fluid clearance.
SO American journal of physiology. Lung cellular and molecular physiology, (2004 Aug) 287 (2) L366-73. Electronic Publication: 2004-04-30. Journal code: 100901229. ISSN: 1040-0605.
AU Chen Xi-Juan; Seth Shaguna; Yue Gang; Kamat Pradip; Compans Richard W; Guidot David; Brown Lou Ann; Eaton Douglas C; Jain Lucky
AN 2004342287 MEDLINE

L37 ANSWER 30 OF 153 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2004184814 ESBIOBASE
TI Influenza virus inhibits ENaC and lung fluid clearance
AU Chen X.-J.; Seth S.; Yue G.; Kamat P.; Compans R.W.; Guidot D.; Brown L.A.; Eaton D.C.; Jain L.
CS L. Jain, Dept. of Pediatrics, Emory Univ. School of Medicine, 2040 Ridgewood Dr., NE, Atlanta, GA 30322, United States. E-mail: Ljain@emory.edu
SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2004), 287/2 31-2 (L366-L373), 34 reference(s) CODEN: APLPE7 ISSN: 1040-0605
DT Journal; Article
CY United States
LA English
SL English

=> d ab 5,8,24,26

L37 ANSWER 5 OF 153 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AB US2005043347 A UPAB: 20050324
NOVELTY - Pyrrole pyridine derivatives (I) and their salts are new.
DETAILED DESCRIPTION - Pyrrole pyridine derivatives of formula (I) and their salts are new.
X = O or S;
Z = C or N;
R1 = H, alkenyl, alkoxyalkynyl, alkoxycarbonyl, alkoxycarbonylalkenyl, alkoxycarbonylalkyl, alkoxycarbonylalkynyl, alkyl, alkynyl, aryl, arylalkenyl, arylalkyl, arylalkynyl, aryloxyalkyl, aryloxyalkynyl, arylsulfanylalkyl, arylsulfanylalkynyl, arylsulfonyloxyalkenyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, CN, cyanoalkenyl, cyanoalkyl, cyanoalkynyl, cycloalkyl, cycloalkylalkoxyalkynyl, cycloalkylalkenyl, cycloalkylalkynyl,

formylalkenyl, formylalkyl, halo, haloalkyl, heteroaryl, heteroarylalkenyl, heteroarylalkyl, heteroarylalkynyl, heteroarylcarbonyl, heteroarylcarbonylalkenyl, heteroarylcarbonylalkyl, heterocyclyl, heterocyclylalkenyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, heterocyclylalkynyl, heterocyclylcarbonyl, heterocyclylcarbonylalkenyl, heterocyclylcarbonylalkyl, heterocyclyloxyalkenyl, hydroxyalkenyl, hydroxyalkyl, hydroxyalkynyl, NR-aR-b, (NR-aR-b)carbonyl, (NR-aR-b)(carbonyl)alkenyl, (NR-aR-b)(carbonyl)alkyl, (NR-aR-b)(carbonyl)alkynyl, (nitro)alkenyl, nitro alkyl or nitroalkynyl;

R2 = H, alkyl or absent;

R3 = (hetero)aryl, heterocyclyl (both optionally substituted with 1-3 of alkoxy, alkyl, CN, halo, haloalkoxy, haloalkyl, (hetero)aryl, heterocyclyl, OH, hydroxyalkyl, LR4 or NR-aR-b) or halo;

L = O, (CH2)mC(O)NR5, NR5C(O)(CH2)m, NR5SO2, SO2NR5, (CH2)mN(R5)C(O)N(R6)(CH2)n or (CH2)mN(R5)C(S)N(R6)(CH2)n (where each group is drawn with its right end attached to R4);

R4 = cycloalkyl, (hetero)aryl, (hetero)arylalkyl or heterocyclyl(alkyl);

R5, R6 = H or alkyl;

R-a, R-b = arylalkyl, aryl (both substituted with 1-5 of alkoxy, alkyl, CN, halo, haloalkoxy, haloalkyl, nitro or oxo), arylalkoxycarbonyl, arylalkoxycarbonylalkyl, arylcarbonyl, arylsulfonyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl (all optionally substituted with 1-5 of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkyl, halo, haloalkoxy, haloalkyl, OH, nitro, NR-cR-d, (NR-cR-d)alkyl, (NR-cR-d)alkylcarbonyl, (NR-cR-d)carbonyl, (NR-cR-d)carbonylalkyl, oxo or spiroheterocyclyl), H, alkenyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylsulfanylalkyl, alkylsulfonyl, carboxyalkyl, formylalkyl, heteroarylsulfonyl, heterocyclylalkylcarbonyl, heterocyclylsulfonyl, hydroxyalkoxyalkyl, hydroxyalkyl, (NR-cR-d)alkyl, (NR-cR-d)alkylcarbonyl, (NR-cR-d)carbonyl or (NR-cR-d)carbonylalkyl;

R-c, R-d = (hetero)aryl, heterocyclyl, (both optionally substituted with 1-5 of alkenyl, alkoxy, alkyl, halo, haloalkoxy, haloalkyl, OH or NO2), H, alkoxy, alkyl, carboxyalkyl, cycloalkyl, haloalkyl, heterocyclylalkyl, hydroxyalkoxyalkyl, hydroxyalkyl or (NR-eR-f)alkyl;

R-e, R-f = H or alkyl; and

m, n = 0-1.

Provided that at least two of the three substituents are other than LR4.

ACTIVITY - Cytostatic; Ophthalmological; Cardiovascular-Gen.; Antidiabetic; Antianemic; Antisickling; Antiinflammatory; Dermatological; Immunosuppressive; Nephrotropic; Gastrointestinal-Gen.; Antiarthritic; Antirheumatic; Osteopathic; Neuroprotective; Antibacterial; Antipsoriatic; Gynecological; Hepatotropic; Antithyroid; Respiratory-Gen.; Antiasthmatic; Vulnerary; Antiemetic; Cerebroprotective; Vasotropic; Virucide; Anti-HIV; Protozoacide; Muscular-Gen.; Anticonvulsant; Hypotensive.

MECHANISM OF ACTION - Protein tyrosine kinase inhibitor. (I) were tested for their kinase insert domain containing receptor (KDR) tyrosine kinase inhibitory activity using complimentary DNAs isolated from HUVEC cells. The results showed that the median inhibitory concentration of (I) was 0.002-50 micro M.

USE - (I) are useful to inhibit one or more protein kinases (KDR, lymphocyte specific protein tyrosine kinase (Lck) (both preferred), Ckit, colony stimulating factor (CSF)-1R, platelet derivative growth factor receptor (PDGFR) beta , PDGFR alpha , Flt-1, Flt-3, Flt-4, Tie-2, **Src**, Fyn, Lyn, Blk, Hck, Fgr, Cot and Yes) and to treat cancers (preferred), ocular conditions, cardiovascular conditions, Crow-Fukase (POEMS) syndrome, diabetic conditions, sickle cell anemia, chronic inflammation, systemic lupus, glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, graft rejection, lyme disease, sepsis, von Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease, polycystic kidney

disease, fibrosis, sarcoidosis, cirrhosis, thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic occlusive pulmonary disease, asthma or **edema** following bums, trauma, radiation, stroke, hypoxia, ischemia, ovarian hyperstimulation syndrome, preeclampsia, menometrorrhagia, endometriosis or infection by Herpes simplex, Herpes Zoster, human immunodeficiency virus diseases, parapoxyvirus, protozoa infection and toxoplasmosis (claimed). (I) are also useful to treat benign and neoplastic proliferative diseases (human cancers of e.g. lung and breast), disorders of the immune system such as autoimmune diseases (e.g. thyroiditis, type 1 diabetes, multiple sclerosis, sarcoidosis, inflammatory bowel disease, Crohn's disease, myasthenia gravis and systemic lupus erythematosus), psoriasis, organ transplant rejection (e.g. kidney rejection, graft versus host disease), hematopoietic malignancies (leukemia and lymphoma), glioblastoma, infantile hemangioma, diseases involving inappropriate vascularization (e.g. diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization due to age-related macular degeneration and infantile hemangiomas), vascular endothelial growth factor mediated **edema**, ascites, effusions, exudates (e.g. macular **edema**, cerebral **edema**, acute lung injury and adult respiratory distress syndrome) and pulmonary hypertension (particularly thromboembolic disease).

ADVANTAGE - (I) has no toxicity, irritation and allergic responses. Dwg.0/0

L37 ANSWER 8 OF 153 MEDLINE on STN DUPLICATE 4

AB Vascular endothelial growth factor (VEGF)-induced **vascular permeability** (VP) is a hallmark of tumor growth and metastasis. Previous studies have shown a requirement for **Src** kinase in VEGF-mediated VP and signaling in blood vessels. In this study, we have examined the effect of **Src**-mediated reduced VP on tumor growth and metastasis. The growth and spontaneous metastasis of VEGF-expressing tumor cells were determined in **Src**-knockout (**src**(-/-)) or control mice (**src**(+/+) or **src**(+/-)). In comparison to control mice, **src**-null mice had a significant reduction in tumor-induced VP as well as a subsequent reduction in spontaneous metastasis. In contrast, primary tumor weight and vascular density were unchanged between **src**-null and control mice. Consistent with a role for **Src** in the extravasation of tumor cells from the circulation, direct intravenous injection of lung carcinoma cells resulted in a more than 2-fold reduction in lung tumor burden in **src**-null mice compared to control mice. The comparison of the results from the experimental metastasis and the spontaneous metastasis models suggests that there are defects in VP in the primary site of **Src** -deficient mice and that there may be an essential role for **Src** and **Src**-mediated VP in tumor metastasis to the lung.

L37 ANSWER 24 OF 153 MEDLINE on STN DUPLICATE 13

AB The synthetic pyrazolopyrimidine, 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP1) is a novel, potent, and selective inhibitor of **Src** family tyrosine kinases. **Vascular permeability** appears to be mediated by vascular endothelial growth factor (VEGF), which requires the activation of downstream **Src** family kinases to exert its function. This study investigates the effects of PP1 on **vascular permeability** and inflammatory response in a rat spinal cord compression model. Ten minutes after compression, PP1 (PP1 group) or the vehicle only (control group) was administered. On days 1, 3, and 7 after compression, the spinal cords were removed and examined histopathologically to determine the expression of VEGF and the extent of **edema** and inflammation. The dryweight method was used to measure the water content of the spinal cords. The mRNA levels of tumor necrosis factor a (TNFalpha) and interleukin 1beta (IL-1beta), which is related to inflammatory responses, were measured with a real-time polymerase chain reaction (RT-PCR) system 6 h after compression. Although VEGF expression was similar in both groups, the

extent of contusional lesion in the PP1 group was reduced by approximately 35% on day 3. Moreover, the water content on days 1, 3, and 7 was significantly reduced and macrophage infiltration on days 3 and 7 was dramatically reduced in the PP1 group. TNF and IL-1beta mRNA expression in the PP1 group were also significantly reduced. These results indicate that PP1 reduces secondary damage after spinal cord injury.

L37 ANSWER 26 OF 153 MEDLINE on STN DUPLICATE 15
AB Ischemia resulting from myocardial infarction (MI) promotes VEGF expression, leading to **vascular permeability** (VP) and **edema**, a process that we show here contributes to tissue injury throughout the ventricle. This permeability/**edema** can be assessed noninvasively by MRI and can be observed at the ultrastructural level as gaps between adjacent endothelial cells. Many of these gaps contain activated platelets adhering to exposed basement membrane, reducing vessel patency. Following MI, genetic or pharmacological blockade of **Src** preserves endothelial cell barrier function, suppressing VP and infarct volume, providing long-term improvement in cardiac function, fibrosis, and survival. To our surprise, an intravascular injection of VEGF into healthy animals, but not those deficient in **Src**, induced similar endothelial gaps, VP, platelet plugs, and some myocyte damage. Mechanistically, we show that quiescent blood vessels contain a complex involving Flk, VE-cadherin, and beta-catenin that is transiently disrupted by VEGF injection. Blockade of **Src** prevents disassociation of this complex with the same kinetics with which it prevents VEGF-mediated VP/**edema.** These findings define a molecular mechanism to account for the **Src** requirement in VEGF-mediated permeability and provide a basis for **Src** inhibition as a therapeutic option for patients with acute MI.

=> s aminopyrazolopyrimidine? or pyrazolopyrimidine? or (aminopyrazolo or pyrazolo)(3w)pyrimidine?
FILE 'MEDLINE'
50 AMINOPYRAZOLOPYRIMIDINE?
94 PYRAZOLOPYRIMIDINE?
141 AMINOPYRAZOLO
990 PYRAZOLO
29241 PYRIMIDINE?
575 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L38 666 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'SCISEARCH'
35 AMINOPYRAZOLOPYRIMIDINE?
152 PYRAZOLOPYRIMIDINE?
102 AMINOPYRAZOLO
2505 PYRAZOLO
21984 PYRIMIDINE?
843 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L39 987 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'LIFESCI'
12 AMINOPYRAZOLOPYRIMIDINE?
34 PYRAZOLOPYRIMIDINE?
14 AMINOPYRAZOLO
158 PYRAZOLO
5854 PYRIMIDINE?
86 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L40 121 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHDS'

```
             0 AMINOPYRAZOLOPYRIMIDINE?
             6 PYRAZOLOPYRIMIDINE?
             3 AMINOPYRAZOLO
            27 PYRAZOLO
           907 PYRIMIDINE?
            23 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L41         28 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOSIS'
            57 AMINOPYRAZOLOPYRIMIDINE?
           162 PYRAZOLOPYRIMIDINE?
           141 AMINOPYRAZOLO
          1841 PYRAZOLO
         21961 PYRIMIDINE?
           700 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L42        861 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'EMBASE'
            47 AMINOPYRAZOLOPYRIMIDINE?
           216 PYRAZOLOPYRIMIDINE?
           176 AMINOPYRAZOLO
          2571 PYRAZOLO
         18893 PYRIMIDINE?
           798 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L43        984 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'HCAPLUS'
           194 AMINOPYRAZOLOPYRIMIDINE?
          1501 PYRAZOLOPYRIMIDINE?
           417 AMINOPYRAZOLO
          5814 PYRAZOLO
         63957 PYRIMIDINE?
          1819 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L44       2487 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'NTIS'
             1 AMINOPYRAZOLOPYRIMIDINE?
             1 PYRAZOLOPYRIMIDINE?
             0 AMINOPYRAZOLO
             5 PYRAZOLO
           529 PYRIMIDINE?
             1 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L45          3 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'ESBIOBASE'
             2 AMINOPYRAZOLOPYRIMIDINE?
            35 PYRAZOLOPYRIMIDINE?
            11 AMINOPYRAZOLO
           355 PYRAZOLO
          5103 PYRIMIDINE?
           160 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L46        194 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
               O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'BIOTECHNO'
            15 AMINOPYRAZOLOPYRIMIDINE?
            27 PYRAZOLOPYRIMIDINE?
            42 AMINOPYRAZOLO
           260 PYRAZOLO
```

```
          5965 PYRIMIDINE?
            85 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L47         119 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
                O OR PYRAZOLO)(3W)PYRIMIDINE?

FILE 'WPIDS'
             2 AMINOPYRAZOLOPYRIMIDINE?
           143 PYRAZOLOPYRIMIDINE?
            53 AMINOPYRAZOLO
          2516 PYRAZOLO
         13541 PYRIMIDINE?
           570 (AMINOPYRAZOLO OR PYRAZOLO)(3W)PYRIMIDINE?
L48         663 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
                O OR PYRAZOLO)(3W)PYRIMIDINE?

TOTAL FOR ALL FILES
L49        7113 AMINOPYRAZOLOPYRIMIDINE? OR PYRAZOLOPYRIMIDINE? OR (AMINOPYRAZOL
                O OR PYRAZOLO)(3W)  PYRIMIDINE?

=> s l49 and src(4a)inhibit?
FILE 'MEDLINE'
         16220 SRC
       1193234 INHIBIT?
          1673 SRC(4A)INHIBIT?
L50        166 L38 AND SRC(4A)INHIBIT?

FILE 'SCISEARCH'
         15142 SRC
        985798 INHIBIT?
          1730 SRC(4A)INHIBIT?
L51        100 L39 AND SRC(4A)INHIBIT?

FILE 'LIFESCI'
          5826 SRC
        323425 INHIBIT?
           585 SRC(4A)INHIBIT?
L52         27 L40 AND SRC(4A)INHIBIT?

FILE 'BIOTECHDS'
           318 SRC
         54401 INHIBIT?
            34 SRC(4A)INHIBIT?
L53          1 L41 AND SRC(4A)INHIBIT?

FILE 'BIOSIS'
         15137 SRC
       1269669 INHIBIT?
          2000 SRC(4A)INHIBIT?
L54         98 L42 AND SRC(4A)INHIBIT?

FILE 'EMBASE'
         11671 SRC
       1080241 INHIBIT?
          1606 SRC(4A)INHIBIT?
L55        171 L43 AND SRC(4A)INHIBIT?

FILE 'HCAPLUS'
         15623 SRC
       1761127 INHIBIT?
          2067 SRC(4A)INHIBIT?
L56        116 L44 AND SRC(4A)INHIBIT?

FILE 'NTIS'
          2030 SRC
```

```
         20752 INHIBIT?
            10 SRC(4A)INHIBIT?
L57          0 L45 AND SRC(4A)INHIBIT?

FILE 'ESBIOBASE'
          8142 SRC
        427731 INHIBIT?
          1371 SRC(4A)INHIBIT?
L58         91 L46 AND SRC(4A)INHIBIT?

FILE 'BIOTECHNO'
          7046 SRC
        301415 INHIBIT?
           754 SRC(4A)INHIBIT?
L59         38 L47 AND SRC(4A)INHIBIT?

FILE 'WPIDS'
           976 SRC
        236898 INHIBIT?
           187 SRC(4A)INHIBIT?
L60          6 L48 AND SRC(4A)INHIBIT?

TOTAL FOR ALL FILES
L61        814 L49 AND SRC(4A) INHIBIT?

=> dup rem l61
PROCESSING COMPLETED FOR L61
L62        280 DUP REM L61 (534 DUPLICATES REMOVED)

=> d 1-100

L62  ANSWER 1 OF 280  HCAPLUS  COPYRIGHT 2005 ACS on STN DUPLICATE 1
TI   Pyrazolo[1,5-a]pyrimidine derivatives, prophylactic or
     therapeutic agents containing them for protein tyrosine kinase-related
     diseases, and combination drugs containing them
SO   Jpn. Kokai Tokkyo Koho, 80 pp.
     CODEN: JKXXAF
IN   Mukoyama, Harunobu; Shiohara, Hiroaki; Nishimura, Toshihiro; Nakayama,
     Akiko; Kikuchi, Shinji; Komatsu, Yoshimitsu; Onoda, Hideki
AN   2005:33492  HCAPLUS
DN   142:127563
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   JP 2005008581        A2    20050113    JP 2003-175930          20030620

L62  ANSWER 2 OF 280     MEDLINE on STN                DUPLICATE 2
TI   p38 kinase-mediated transactivation of the epidermal growth factor
     receptor is required for dedifferentiation of renal epithelial cells after
     oxidant injury.
SO   Journal of biological chemistry, (2005 Jun 3) 280 (22) 21036-42.
     Electronic Publication: 2005-03-28.
     Journal code: 2985121R. ISSN: 0021-9258.
AU   Zhuang Shougang; Yan Yan; Han Jiahuai; Schnellmann Rick G
AN   2005279091     MEDLINE

L62  ANSWER 3 OF 280  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
TI   Src-mediated tyrosine phosphorylation of p47(phox) in hyperoxia-induced
     activation of NADPH oxidase and generation of reactive oxygen species in
     lung endothelial cells.
SO   Journal of Biological Chemistry, (27 May 2005) Vol. 280, No. 21, pp.
     20700-20711.
     Refs: 53
     ISSN: 0021-9258  CODEN: JBCHA3
```

AU Chowdhury A.K.; Watkins T.; Parinandi N.L.; Saatian B.; Kleinberg M.E.; Usatyuk P.V.; Natarajan V.
AN 2005250924 EMBASE

L62 ANSWER 4 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Survival function of protein kinase Cι, as a novel nitrosamine 4-(methylinitrosamino) -1-(3-pyridyl)-1-butanone-activated bad kinase.
SO Journal of Biological Chemistry, (22 Apr 2005) Vol. 280, No. 16, pp. 16045-16052.
Refs: 51
ISSN: 0021-9258 CODEN: JBCHA3
AU Jin Z.; Xin M.; Deng X.
AN 2005206818 EMBASE

L62 ANSWER 5 OF 280 MEDLINE on STN DUPLICATE 3
TI Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases.
SO Journal of biological chemistry, (2005 Apr 8) 280 (14) 14130-7.
Electronic Publication: 2005-01-25.
Journal code: 2985121R. ISSN: 0021-9258.
AU Vertino Anthony M; Bula Craig M; Chen Jin-Ran; Almeida Maria; Han Li; Bellido Teresita; Kousteni Stavroula; Norman Anthony W; Manolagas Stavros C
AN 2005173203 MEDLINE

L62 ANSWER 6 OF 280 MEDLINE on STN DUPLICATE 4
TI Flow shear stress stimulates Gab1 tyrosine phosphorylation to mediate protein kinase B and endothelial nitric-oxide synthase activation in endothelial cells.
SO Journal of biological chemistry, (2005 Apr 1) 280 (13) 12305-9.
Electronic Publication: 2005-01-21.
Journal code: 2985121R. ISSN: 0021-9258.
AU Jin Zheng-Gen; Wong Chelsea; Wu Jie; Berk Bradford C
AN 2005160658 MEDLINE

L62 ANSWER 7 OF 280 MEDLINE on STN DUPLICATE 5
TI Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB.
SO Journal of biological chemistry, (2005 Apr 1) 280 (13) 12145-51.
Electronic Publication: 2005-01-28.
Journal code: 2985121R. ISSN: 0021-9258.
AU Courter Donald L; Lomas Lucy; Scatena Marta; Giachelli Cecilia M
AN 2005160711 MEDLINE

L62 ANSWER 8 OF 280 MEDLINE on STN
TI Involvement of c-Src and protein kinase C delta in the inhibition of Cl(-)/OH- exchange activity in Caco-2 cells by serotonin.
SO Journal of biological chemistry, (2005 Mar 25) 280 (12) 11859-68.
Electronic Publication: 2005-01-06.
Journal code: 2985121R. ISSN: 0021-9258.
AU Saksena Seema; Gill Ravinder K; Tyagi Sangeeta; Alrefai Waddah A; Sarwar Zaheer; Ramaswamy Krishnamurthy; Dudeja Pradeep K
AN 2005146181 MEDLINE

L62 ANSWER 9 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI **Inhibition** of **Src**-like kinases reveals Akt-dependent and -independent pathways in insulin-like growth factor I-mediated oligodendrocyte progenitor survival.
SO Journal of Biological Chemistry, (11 Mar 2005) Vol. 280, No. 10, pp. 8918-8928.

Refs: 67
ISSN: 0021-9258 CODEN: JBCHA3
AU Cui Q.-L.; Zheng W.-H.; Quirion R.; Almazan G.
AN 2005138590 EMBASE

L62 ANSWER 10 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Internalization and Src activity regulate the time course of ERK activation, by delta opioid receptor ligands.
SO Journal of Biological Chemistry, (4 Mar 2005) Vol. 280, No. 9, pp. 7808-7816.
Refs: 39
ISSN: 0021-9258 CODEN: JBCHA3
AU Audet N.; Paquin-Gobeil M.; Landry-Paquet O.; Schiller P.W.; Pineyro G.
AN 2005118846 EMBASE

L62 ANSWER 11 OF 280 MEDLINE on STN DUPLICATE 6
TI Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells.
SO Journal of biological chemistry, (2005 Mar 4) 280 (9) 7729-38. Electronic Publication: 2004-12-23.
Journal code: 2985121R. ISSN: 0021-9258.
AU Amos Samson; Martin Patrick M; Polar Gregory A; Parsons Sarah J; Hussaini Isa M
AN 2005104092 MEDLINE

L62 ANSWER 12 OF 280 MEDLINE on STN DUPLICATE 7
TI Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase.
SO Journal of neuroscience : official journal of the Society for Neuroscience, (2005 Jul 13) 25 (28) 6584-93.
Journal code: 8102140. ISSN: 1529-2401.
AU Derkinderen Pascal; Scales Timothy M E; Hanger Diane P; Leung Kit-Yi; Byers Helen L; Ward Malcolm A; Lenz Christof; Price Caroline; Bird Ian N; Perera Timothy; Kellie Stuart; Williamson Ritchie; Noble Wendy; Van Etten Richard A; Leroy Karelle; Brion Jean-Pierre; Reynolds C Hugh; Anderton Brian H
AN 2005360848 IN-PROCESS

L62 ANSWER 13 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.
SO Molecular and Cellular Biology, (2005) Vol. 25, No. 12, pp. 4826-4840.
Refs: 59
ISSN: 0270-7306 CODEN: MCEBD4
AU Proietti C.; Salatino M.; Rosemblit C.; Carnevale R.; Pecci A.; Kornblihtt A.R.; Molinolo A.A.; Frahm I.; Charreau E.H.; Schillaci R.; Elizalde P.V.
AN 2005253451 EMBASE

L62 ANSWER 14 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: Implications for lymphomagenesis.
SO Blood, (15 May 2005) Vol. 105, No. 10, pp. 3987-3994.
Refs: 58
ISSN: 0006-4971 CODEN: BLOOAW
AU Prakash O.; Swamy O.R.; Peng X.; Tang Z.-Y.; Li L.; Larson J.E.; Cohen J.C.; Gill J.; Farr G.; Wang S.; Samaniego F.
AN 2005214569 EMBASE

L62 ANSWER 15 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS

RESERVED. on STN
TI Inhibition of granulocyte-macrophage colony-stimulating factor signaling and microglial proliferation by anti-CD45RO: Role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt.
SO Journal of Immunology, (1 Mar 2005) Vol. 174, No. 5, pp. 2712-2719.
Refs: 77
ISSN: 0022-1767 CODEN: JOIMA3
AU Suh H.-S.; Kim M.-O.; Lee S.C.
AN 2005092503 EMBASE

L62 ANSWER 16 OF 280 MEDLINE on STN DUPLICATE 8
TI A **Src** family **inhibitor** (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells.
SO Life sciences, (2005 Apr 22) 76 (23) 2711-20. Electronic Publication: 2005-01-28.
Journal code: 0375521. ISSN: 0024-3205.
AU Fujimoto Eriko; Sato Hiromi; Nagashima Yoji; Negishi Etsuko; Shirai Sumiko; Fukumoto Keiko; Hagiwara Hiromi; Hagiwara Kiyokazu; Ueno Koichi; Yano Tomohiro
AN 2005161031 MEDLINE

L62 ANSWER 17 OF 280 MEDLINE on STN DUPLICATE 9
TI Antagonistic regulation of swelling-activated Cl- current in rabbit ventricle by Src and EGFR protein tyrosine kinases.
SO American journal of physiology. Heart and circulatory physiology, (2005 Jun) 288 (6) H2628-36. Electronic Publication: 2005-01-28.
Journal code: 100901228. ISSN: 0363-6135.
AU Ren Zuojun; Baumgarten Clive M
AN 2005255347 MEDLINE

L62 ANSWER 18 OF 280 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2005137626 ESBIOBASE
TI Antagonistic regulation of swelling-activated Cl.sup.- current in rabbit ventricle by Src and EGFR protein tyrosine kinases
AU Ren Z.; Baumgarten C.M.
CS C.M. Baumgarten, Dept. of Physiology, Medical College of Virginia, Virginia Commonwealth Univ., 1101 E. Marshall St., Richmond, VA 23298, China.
E-mail: clive.baumgarten@vcu.edu
SO American Journal of Physiology - Heart and Circulatory Physiology, (2005), 288/6 57-6 (H2628-H2636), 61 reference(s)
CODEN: AJPPDI ISSN: 0363-6135
DT Journal; Article
CY United States
LA English
SL English

L62 ANSWER 19 OF 280 MEDLINE on STN DUPLICATE 10
TI Cell cycle signaling by endothelin-1 requires Src nonreceptor protein tyrosine kinase.
SO Molecular pharmacology, (2005 Jun) 67 (6) 2049-56. Electronic Publication: 2005-03-16.
Journal code: 0035623. ISSN: 0026-895X.
AU Mishra Rangnath; Wang Yuan; Simonson Michael S
AN 2005256843 MEDLINE

L62 ANSWER 20 OF 280 MEDLINE on STN
TI Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells.
SO FEBS letters, (2005 Mar 28) 579 (9) 1995-2000.
Journal code: 0155157. ISSN: 0014-5793.
AU Ito Sachiko; Sawada Makoto; Haneda Masataka; Fujii Satoshi; Oh-Hashi

Kentaro; Kiuchi Kazutoshi; Takahashi Masahide; Isobe Ken-Ichi
AN 2005160445 MEDLINE

L62 ANSWER 21 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis.
SO Cancer Research, (1 Mar 2005) Vol. 65, No. 5, pp. 1858-1867.
Refs: 56
ISSN: 0008-5472 CODEN: CNREA8
AU Tan M.; Li P.; Klos K.S.; Lu J.; Lan K.-H.; Nagata Y.; Fang D.; Jing T.; Yu D.
AN 2005159875 EMBASE

L62 ANSWER 22 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
SO Cancer Research, (1 Mar 2005) Vol. 65, No. 5, pp. 1849-1857.
Refs: 50
ISSN: 0008-5472 CODEN: CNREA8
AU Pandini G.; Mineo R.; Frasca F.; Roberts Jr. C.T.; Marcelli M.; Vigneri R.; Belfiore A.
AN 2005159874 EMBASE

L62 ANSWER 23 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Identification of tyrosine-phosphorylated proteins of the mitochondrial oxidative phosphorylation machinery.
SO Cellular and Molecular Life Sciences, (2005) Vol. 62, No. 13, pp. 1478-1488.
Refs: 44
ISSN: 1420-682X CODEN: CMLSFI
AU Augereau O.; Claverol S.; Boudes N.; Basurko M.-J.; Bonneu M.; Rossignol R.; Mazat J.-P.; Letellier T.; Dachary-Prigent J.
AN 2005299304 EMBASE

L62 ANSWER 24 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesis.
SO Journal of Neurochemistry, (2005) Vol. 92, No. 6, pp. 1463-1476.
Refs: 83
ISSN: 0022-3042 CODEN: JONRA
AU Loers G.; Chen S.; Grumet M.; Schachner M.
AN 2005132801 EMBASE

L62 ANSWER 25 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI A possible signal transduction pathway for cyclin D2 expression by a pectic polysaccharide from the roots of Bupleurum falcatum L. in murine B cell.
SO International Immunopharmacology, (2005) Vol. 5, No. 9, pp. 1373-1386.
Refs: 38
ISSN: 1567-5769 CODEN: IINMBA
AU Matsumoto T.; Hosono-Nishiyama K.; Guo Y.-J.; Ikejima T.; Yamada H.
AN 2005263958 EMBASE

L62 ANSWER 26 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Hyposmolarity-induced ErbB4 phosphorylation and its influence on the non-receptor tyrosine kinase network response in cultured cerebellar granule neurons.
SO Journal of Neurochemistry, (2005) Vol. 93, No. 5, pp. 1189-1198.

Refs: 40
ISSN: 0022-3042 CODEN: JONRA
AU Lezama R.; Ortega A.; Ordaz B.; Pasantes-Morales H.
AN 2005250722 EMBASE

L62 ANSWER 27 OF 280 MEDLINE on STN DUPLICATE 11
TI Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts.
SO Journal of pharmacology and experimental therapeutics, (2005 Mar) 312 (3) 1179-86. Electronic Publication: 2004-12-01.
Journal code: 0376362. ISSN: 0022-3565.
AU Purdom Sally; Chen Qin M
AN 2005084438 MEDLINE

L62 ANSWER 28 OF 280 MEDLINE on STN DUPLICATE 12
TI **Src** family kinase **inhibitors** block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.
SO Molecular pharmacology, (2005 Apr) 67 (4) 1145-57. Electronic Publication: 2004-12-22.
Journal code: 0035623. ISSN: 0026-895X.
AU Kansra Sanjay; Stoll Stefan W; Johnson Jessica L; Elder James T
AN 2005149679 MEDLINE

L62 ANSWER 29 OF 280 MEDLINE on STN DUPLICATE 13
TI H(2)O(2)-Induced Phosphorylation of ERK1/2 and PKB Requires Tyrosine Kinase Activity of Insulin Receptor and c-Src.
SO Antioxidants & redox signalling, (2005 Jul-Aug) 7 (7-8) 1014-20.
Journal code: 100888899. ISSN: 1523-0864.
AU Mehdi Mohamad Z; Pandey Nihar R; Pandey Sanjay K; Srivastava Ashok K
AN 2005346374 IN-PROCESS

L62 ANSWER 30 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Modulation of the cardiac sodium channel Na(v)1.5 by Fyn, a Src family tyrosine kinase.
SO Circulation Research, (13 Mar 2005) Vol. 96, No. 9, pp. 991-998.
Refs: 32
ISSN: 0009-7330 CODEN: CIRUAL
AU Ahern C.A.; Zhang J.-F.; Wookalis M.J.; Horn R.
AN 2005231105 EMBASE

L62 ANSWER 31 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells.
SO Biochemical and Biophysical Research Communications, (25 Feb 2005) Vol. 327, No. 4, pp. 971-978.
Refs: 49
ISSN: 0006-291X CODEN: BBRCA
AU Montiel M.; Perez De La Blanca E.; Jimenez E.
AN 2005044380 EMBASE

L62 ANSWER 32 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Pigment epithelium-derived factor inhibits fibroblast-growth-factor-2-induced capillary morphogenesis of endothelial cells through Fyn.
SO Journal of Cell Science, (1 Mar 2005) Vol. 118, No. 5, pp. 961-970.
Refs: 50
ISSN: 0021-9533 CODEN: JNCSAI
AU Kanda S.; Mochizuki Y.; Nakamura T.; Miyata Y.; Matsuyama T.; Kanetake H.
AN 2005160278 EMBASE

L62 ANSWER 33 OF 280 HCAPLUS COPYRIGHT 2005 ACS on STN
TI Isoproterenol induces actin depolymerization in human airway smooth muscle cells via activation of an Src kinase and Gs
SO American Journal of Physiology (2005), 288(5, Pt. 1), L924-L931
CODEN: AJPHAP; ISSN: 0002-9513
AU Hirshman, Carol A.; Zhu, Defen; Pertel, Thomas; Panettieri, Reynold A.; Emala, Charles W.
AN 2005:430464 HCAPLUS
DN 142:427263

L62 ANSWER 34 OF 280 MEDLINE on STN DUPLICATE 14
TI Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.
SO Toxicological sciences : an official journal of the Society of Toxicology, (2005 Jun) 85 (2) 916-26. Electronic Publication: 2005-03-16.
Journal code: 9805461. ISSN: 1096-6080.
AU Zhou Hui-Ren; Jia Qunshan; Pestka James J
AN 2005259708 IN-PROCESS

L62 ANSWER 35 OF 280 MEDLINE on STN DUPLICATE 15
TI Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts.
SO Journal of investigative dermatology, (2005 May) 124 (5) 886-92.
Journal code: 0426720. ISSN: 0022-202X.
AU Mimura Yoshihiro; Ihn Hironobu; Jinnin Masatoshi; Asano Yoshihide; Yamane Kenichi; Tamaki Kunihiko
AN 2005220885 MEDLINE

L62 ANSWER 36 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI **Inhibition** of the **Src** and Jak kinases protects against lipopolysaccharide- induced acute lung injury.
SO American Journal of Respiratory and Critical Care Medicine, (15 Apr 2005) Vol. 171, No. 8, pp. 858-867.
Refs: 66
ISSN: 1073-449X CODEN: AJCMED
AU Severgnini M.; Takahashi S.; Tu P.; Perides G.; Homer R.J.; Jhung J.W.; Bhavsar D.; Cochran B.H.; Simon A.R.
AN 2005187386 EMBASE

L62 ANSWER 37 OF 280 MEDLINE on STN DUPLICATE 16
TI Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes.
SO Cardiovascular research, (2005 Mar 1) 65 (4) 803-12.
Journal code: 0077427. ISSN: 0008-6363.
AU Xu Zhelong; Park Sung-Sik; Mueller Robert A; Bagnell Robert C; Patterson Cam; Boysen Philip G
AN 2005091088 MEDLINE

L62 ANSWER 38 OF 280 MEDLINE on STN DUPLICATE 17
TI Suppression of CD4+ T cell activation by a novel **inhibitor** of **Src** family kinases.
SO International immunopharmacology, (2005 Apr) 5 (4) 667-77.
Journal code: 100965259. ISSN: 1567-5769.
AU McRae Bradford L; Wallace Craig; Dixon Kathleen Fitzgerald; Roux Alyson; Mohan Sukumari; Jia Yong; Presky David H; Tracey Daniel E; Hirst Gavin C
AN 2005081819 MEDLINE

L62 ANSWER 39 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Differential regulation of vascular focal adhesion kinase by steady stretch and pulsatility.
SO Circulation, (8 Feb 2005) Vol. 111, No. 5, pp. 643-649.
Refs: 25

ISSN: 0009-7322 CODEN: CIRCAZ
AU Lehoux S.; Esposito B.; Merval R.; Tedgui A.
AN 2005072390 EMBASE

L62 ANSWER 40 OF 280 MEDLINE on STN DUPLICATE 18
TI Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases.
SO Journal of pharmacology and experimental therapeutics, (2005 May) 313 (2) 594-603. Electronic Publication: 2005-01-19.
Journal code: 0376362. ISSN: 0022-3565.
AU Wittmann Marion; Marino Michael J; Henze Darrell A; Seabrook Guy R; Conn P Jeffrey
AN 2005198172 MEDLINE

L62 ANSWER 41 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
SO Journal of Endocrinology, (2005) Vol. 185, No. 3, pp. 577-592.
Refs: 75
ISSN: 0022-0795 CODEN: JOENAK
AU Gilad L.A.; Bresler T.; Gnainsky J.; Smirnoff P.; Schwartz B.
AN 2005286503 EMBASE

L62 ANSWER 42 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Bradykinin-induced p42/p44 MAPK phosphorylation and cell proliferation via Src, EGF receptors, and PI3-K/Akt in vascular smooth muscle cells.
SO Journal of Cellular Physiology, (2005) Vol. 203, No. 3, pp. 538-546.
Refs: 47
ISSN: 0021-9541 CODEN: JCLLAX
AU Yang C.-M.; Lin M.-I.; Hsieh H.-L.; Sun C.-C.; Ma Y.-H.; Hsiao L.-D.
AN 2005209801 EMBASE

L62 ANSWER 43 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Activation of the β-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
SO Cancer Research, (15 Jan 2005) Vol. 65, No. 2, pp. 526-532.
Refs: 45
ISSN: 0008-5472 CODEN: CNREA8
AU Maupas-Schwalm F.; Robinet C.; Auge N.; Thiers J.-C.; Garcia V.; Cambus J.-P.; Salvayre R.; Negre-Salvayre A.
AN 2005050174 EMBASE

L62 ANSWER 44 OF 280 MEDLINE on STN DUPLICATE 19
TI Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies.
SO Farmaco (Societa chimica italiana : 1989), (2005 Jun-Jul) 60 (6-7) 497-506.
Journal code: 8912641. ISSN: 0014-827X.
AU Olgen Sureyya; Akaho Eiichi; Nebioglu Dogu
AN 2005391494 IN-PROCESS

L62 ANSWER 45 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Stromal cell-derived factor-1α/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1.
SO Blood, (15 Jan 2005) Vol. 105, No. 2, pp. 474-480.
Refs: 37

ISSN: 0006-4971 CODEN: BLOOAW
AU Okabe S.; Fukuda S.; Kim Y.-J.; Niki M.; Pelus L.M.; Ohyashiki K.; Pandolfi P.P.; Broxmeyer H.E.
AN 2005022230 EMBASE

L62 ANSWER 46 OF 280 MEDLINE on STN DUPLICATE 20
TI Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes.
SO American journal of physiology. Heart and circulatory physiology, (2005 Jul) 289 (1) H361-7. Electronic Publication: 2005-02-11.
Journal code: 100901228. ISSN: 0363-6135.
AU Das Samarjit; Powell Saul R; Wang Ping; Divald Andras; Nesaretnam Kalanithi; Tosaki Arpad; Cordis Gerald A; Maulik Nilanjana; Das Dipak K
AN 2005312774 IN-PROCESS

L62 ANSWER 47 OF 280 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2005176965 ESBIOBASE
TI Cardioprotection with palm tocotrienol: Antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes
AU Das S.; Powell S.R.; Wang P.; Divald A.; Nesaretnam K.; Tosaki A.; Cordis G.A.; Maulik N.; Das D.K.
CS D.K. Das, Cardiovascular Research Center, Univ. of Connecticut, School of Medicine, Farmington, CT 06030-1110, United States.
E-mail: ddas@neuron.uchc.edu
SO American Journal of Physiology - Heart and Circulatory Physiology, (2005), 289/1 58-1 (H361-H367), 41 reference(s)
CODEN: AJPPDI ISSN: 0363-6135
DT Journal; Article
CY United States
LA English
SL English

L62 ANSWER 48 OF 280 MEDLINE on STN
TI Protein kinases and adherens junction dynamics in the seminiferous epithelium of the rat testis.
SO Journal of cellular physiology, (2005 Feb) 202 (2) 344-60.
Journal code: 0050222. ISSN: 0021-9541.
AU Lee Nikki P Y; Cheng C Yan
AN 2004596151 MEDLINE

L62 ANSWER 49 OF 280 MEDLINE on STN
TI c-Src and hydrogen peroxide mediate transforming growth factor-beta1-induced smooth muscle cell-gene expression in 10T1/2 cells.
SO Arteriosclerosis, thrombosis, and vascular biology, (2005 Feb) 25 (2) 341-7. Electronic Publication: 2004-12-09.
Journal code: 9505803. ISSN: 1524-4636.
AU Sato Mahito; Kawai-Kowase Keiko; Sato Hiroko; Oyama Yuko; Kanai Hiroyoshi; Ohyama Yoshio; Suga Tatsuo; Maeno Toshitaka; Aoki Yasuhiro; Tamura Junichi; Sakamoto Hironosuke; Nagai Ryozo; Kurabayashi Masahiko
AN 2005052056 MEDLINE

L62 ANSWER 50 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis.
SO Journal of Hypertension, (2005) Vol. 23, No. 2, pp. 329-335.
Refs: 40
ISSN: 0263-6352 CODEN: JOHYD3
AU Beaucage P.; Iglarz M.; Servant M.; Touyz R.M.; Moreau P.
AN 2005092453 EMBASE

L62 ANSWER 51 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Identification and phenotypic characterization of a subpopulation of T84 human colon cancer cells, after selection on activated endothelial cells.
SO Journal of Cellular Physiology, (2005) Vol. 203, No. 1, pp. 261-272.
Refs: 50
ISSN: 0021-9541 CODEN: JCLLAX
AU Alessandro R.; Flugy A.M.; Russo D.; Stassi G.; De Leo A.; Corrado C.; Alaimo G.; De Leo G.
AN 2005110899 EMBASE

L62 ANSWER 52 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Gastric mucin secretion in response to β-adrenergic G protein-coupled receptor activation is mediated by SRC kinase-dependent epidermal growth factor receptor transactivation.
SO Journal of Physiology and Pharmacology, (2005) Vol. 56, No. 2, pp. 247-258.
Refs: 32
ISSN: 0867-5910 CODEN: JPHPEI
AU Slomiany B.L.; Slomiany A.
AN 2005296057 EMBASE

L62 ANSWER 53 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Somatostatin-induced activation and up-regulation of N-methyl-D-aspartate receptor function: Mediation through calmodulin-dependent protein kinase II, phospholipase C, protein kinase C, and tyrosine kinase in hippocampal noradrenergic nerve endings.
SO Journal of Pharmacology and Experimental Therapeutics, (2005) Vol. 313, No. 1, pp. 242-249.
Refs: 40
ISSN: 0022-3565 CODEN: JPETAB
AU Pittaluga A.; Feligioni M.; Longordo F.; Arvigo M.; Raiteri M.
AN 2005140147 EMBASE

L62 ANSWER 54 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI **Src inhibition** enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
SO Molecular Cancer Therapeutics, (2005) Vol. 4, No. 2, pp. 217-224.
Refs: 34
ISSN: 1535-7163 CODEN: MCTOCF
AU Chen T.; Pengetnze Y.; Taylor C.C.
AN 2005113552 EMBASE

L62 ANSWER 55 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI α-Crystallin localizes to the leading edges of migrating lens epithelial cells.
SO Experimental Cell Research, (15 May 2005) Vol. 306, No. 1, pp. 203-215.
Refs: 48
ISSN: 0014-4827 CODEN: ECREAL
AU Maddala R.; Rao P.V.
AN 2005224528 EMBASE

L62 ANSWER 56 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI 17β-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity.
SO Endocrinology, (2005) Vol. 146, No. 1, pp. 201-207.
Refs: 40
ISSN: 0013-7227 CODEN: ENDOAO
AU Kennedy A.M.; Shogren K.L.; Zhang M.; Turner R.T.; Spelsberg T.C.; Maran A.

AN 2005014881 EMBASE

L62 ANSWER 57 OF 280 MEDLINE on STN DUPLICATE 21
TI Inhibition of tyrosine phosphorylation blocks hormone-stimulated calcium influx in an insect steroidogenic gland.
SO Molecular and cellular endocrinology, (2005 Jan 14) 229 (1-2) 185-92. Journal code: 7500844. ISSN: 0303-7207.
AU Priester Jennifer; Smith Wendy A
AN 2004632861 MEDLINE

L62 ANSWER 58 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Modulation of cell adhesion molecules in various epithelial cell lines after treatment with PP2.
SO Molecular Pharmaceutics, (2005) Vol. 2, No. 3, pp. 170-184.
Refs: 42
ISSN: 1543-8384
AU Calcagno A.M.; Fostel J.M.; Orchekowski R.P.; Alston J.T.; Mattes W.B.; Siahaan T.J.; Ware J.A.
AN 2005297704 EMBASE

L62 ANSWER 59 OF 280 MEDLINE on STN
TI Activation of STAT5-dependent transcription by the neurotrophin receptor Trk.
SO Journal of neurobiology, (2005 May) 63 (2) 159-71. Journal code: 0213640. ISSN: 0022-3034.
AU Klein Mathias; Hempstead Barbara L; Teng Kenneth K
AN 2005176696 MEDLINE

L62 ANSWER 60 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Extinction and reacquisition of a fear-motivated memory require activity of the Src family of tyrosine kinases in the CA1 region of the hippocampus.
SO Pharmacology Biochemistry and Behavior, (2005) Vol. 81, No. 1, pp. 139-145.
Refs: 71
ISSN: 0091-3057 CODEN: PBBHAU
AU Bevilaqua L.R.M.; Da Silva W.N.; Medina J.H.; Izquierdo I.; Cammarota M.
AN 2005231893 EMBASE

L62 ANSWER 61 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Transactivation of the epidermal growth factor receptor mediates muscarinic stimulation of focal adhesion kinase in intestinal epithelial cells.
SO Journal of Cellular Physiology, (2005) Vol. 203, No. 1, pp. 103-110.
Refs: 56
ISSN: 0021-9541 CODEN: JCLLAX
AU Calandrella S.O.; Barrett K.E.; Keely S.J.
AN 2005110883 EMBASE

L62 ANSWER 62 OF 280 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN DUPLICATE 22
TI Bombesin and angiotensin II rapidly stimulate Src phosphorylation at Tyr-418 in fibroblasts and intestinal epithelial cells through a PP2-insensitive pathway.
SO Cellular Signalling, (January 2005) Vol. 17, No. 1, pp. 93-102. print.
ISSN: 0898-6568 (ISSN print).
AU Wu, Steven S.; Yamauchi, Ken; Rozengurt, Enrique [Reprint Author]
AN 2005:35162 BIOSIS

L62 ANSWER 63 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI β(3)-Adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation.
SO Experimental Eye Research, (2005) Vol. 80, No. 1, pp. 83-91.
Refs: 19
ISSN: 0014-4835 CODEN: EXERA6
AU Steinle J.J.; Zamora D.O.; Rosenbaum J.T.; Granger H.J.
AN 2005040237 EMBASE

L62 ANSWER 64 OF 280 MEDLINE on STN
TI The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL.
SO Molecules and cells, (2005 Feb 28) 19 (1) 60-6.
Journal code: 9610936. ISSN: 1016-8478.
AU Cho Hyun-Mi; Choi Sung Hee; Hwang Ki-Chul; Oh Sue-Young; Kim Ho-Gyung; Yoon Deok-Hyo; Choi Myung-Ae; Lim Soyeon; Song Heesang; Jang Yangsoo; Kim Tae Woong
AN 2005119752 MEDLINE

L62 ANSWER 65 OF 280 MEDLINE on STN DUPLICATE 23
TI Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases.
SO Cellular signalling, (2005 Jan) 17 (1) 39-48.
Journal code: 8904683. ISSN: 0898-6568.
AU Backlund Maria; Ingelman-Sundberg Magnus
AN 2004482366 MEDLINE

L62 ANSWER 66 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Cardioprotection with palm tocotrienol: Antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes.
SO American Journal of Physiology - Heart and Circulatory Physiology, (2005) Vol. 289, No. 1 58-1, pp. H361-H367.
Refs: 41
ISSN: 0363-6135 CODEN: AJPPDI
AU Das S.; Powell S.R.; Wang P.; Divald A.; Nesaretnam K.; Tosaki A.; Cordis G.A.; Maulik N.; Das D.K.
AN 2005301893 EMBASE

L62 ANSWER 67 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Antagonistic regulation of swelling-activated Cl(-) current in rabbit ventricle by Src and EGFR protein tyrosine kinases.
SO American Journal of Physiology - Heart and Circulatory Physiology, (2005) Vol. 288, No. 6 57-6, pp. H2628-H2636.
Refs: 61
ISSN: 0363-6135 CODEN: AJPPDI
AU Ren Z.; Baumgarten C.M.
AN 2005233316 EMBASE

L62 ANSWER 68 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Isoproterenol induces actin depolymerization in human airway smooth muscle cells via activation of an Src kinase and G(S).
SO American Journal of Physiology - Lung Cellular and Molecular Physiology, (2005) Vol. 288, No. 5 32-5, pp. L924-L931.
Refs: 45
ISSN: 1040-0605 CODEN: APLPE7
AU Hirshman C.A.; Zhu D.; Pertel T.; Panettieri R.A.; Emala C.W.
AN 2005183732 EMBASE

L62 ANSWER 69 OF 280 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
TI Identifying therapeutic compound for treating Alzheimer's disease, involves providing **Src** protein and determining **inhibitory** effect of compound on **Src** activity;

recombinant protein production for use in drug screening and disease therapy
AU MERCKEN L; ZAMBRANO N; RUSSO T
AN 2004-14884 BIOTECHDS
PI EP 1413887 28 Apr 2004

L62 ANSWER 70 OF 280 HCAPLUS COPYRIGHT 2005 ACS on STN
TI 4-Amino-substituted derivatives of **pyrazolo**[3,4-d] **pyrimidine** and pyrrolo[2,3-d]pyrimidine and their preparation, pharmaceutical compositions, and use as antitumor and antileukemic agents
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
IN Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Manetti, Fabrizio; Schenone, Silvia; Carraro, Fabio
AN 2004:1059356 HCAPLUS
DN 142:38272

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004106340	A2	20041209	WO 2004-IT303	20040526
WO 2004106340	A3	20050217		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L62 ANSWER 71 OF 280 HCAPLUS COPYRIGHT 2005 ACS on STN
TI Method using a **Src** family tyrosine kinase **inhibitor** for the treatment of myocardial infarction
SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of Appl. No. PCT/US03/37653.
CODEN: USXXCO
IN Cheresh, David A.; Paul, Robert; Eliceiri, Brian
AN 2004:905617 HCAPLUS
DN 141:374724

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004214836	A1	20041028	US 2004-801050	20040315
WO 9961590	A1	19991202	WO 1999-US11780	19990528

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6685938	B1	20040203	US 1999-470881	19991222
US 2003130209	A1	20030710	US 2002-298377	20021118
WO 2004045563	A2	20040603	WO 2003-US37653	20031118
WO 2004045563	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L62 ANSWER 72 OF 280 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
TI Use of an inhibitor of vascular endothelial growth factor-mediated vascular permeability e.g. a **pyrazolopyrimidine** or 4-anilino-3-quinolinecarbonitrile derivative to treat, prevent or reduce reperfusion injury or post-pump syndrome.
PI WO 2004032709 A2 20040422 (200432)* EN 62 A61B000-00
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
AU 2003279795 A1 20040504 (200465) A61B000-00
IN LORSORDO, D W; LOSORDO, D W

L62 ANSWER 73 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin.
SO Journal of Biological Chemistry, (17 Dec 2004) Vol. 279, No. 51, pp. 53516-53523.
Refs: 65
ISSN: 0021-9258 CODEN: JBCHA3
AU Melendez J.; Turner C.; Avraham H.; Steinberg S.F.; Schaefer E.; Sussman M.A.
AN 2005014999 EMBASE

L62 ANSWER 74 OF 280 MEDLINE on STN DUPLICATE 25
TI **Src** tyrosine kinase **inhibitor** PP2 markedly enhances Ras-independent activation of Raf-1 protein kinase by phorbol myristate acetate and H2O2.
SO Journal of biological chemistry, (2004 Nov 19) 279 (47) 48692-701.
Electronic Publication: 2004-09-08.
Journal code: 2985121R. ISSN: 0021-9258.
AU Lee Michael; Kim Ji-Young; Anderson Wayne B
AN 2004569790 MEDLINE

L62 ANSWER 75 OF 280 MEDLINE on STN DUPLICATE 26
TI Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities.
SO Journal of biological chemistry, (2004 Sep 10) 279 (37) 39175-85.
Electronic Publication: 2004-07-06.
Journal code: 2985121R. ISSN: 0021-9258.
AU Le Boeuf Fabrice; Houle Francois; Huot Jacques
AN 2004441218 MEDLINE

L62 ANSWER 76 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Extracellular oxidation by taurine chloramine activates ERK via the epidermal growth factor receptor.
SO Journal of Biological Chemistry, (30 Jul 2004) Vol. 279, No. 31, pp. 32205-32211.
Refs: 52
ISSN: 0021-9258 CODEN: JBCHA3
AU Midwinter R.G.; Peskin A.V.; Vissers M.C.M.; Winterbourn C.C.
AN 2004333203 EMBASE

L62 ANSWER 77 OF 280 MEDLINE on STN DUPLICATE 27

TI Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation.
SO Journal of biological chemistry, (2004 Jul 16) 279 (29) 30588-99. Electronic Publication: 2004-04-19. Journal code: 2985121R. ISSN: 0021-9258.
AU Boutahar Nadia; Guignandon Alain; Vico Laurence; Lafage-Proust Marie-Helene
AN 2004343375 MEDLINE

L62 ANSWER 78 OF 280 MEDLINE on STN DUPLICATE 28
TI Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.
SO Journal of biological chemistry, (2004 Jun 25) 279 (26) 27088-97. Electronic Publication: 2004-04-21. Journal code: 2985121R. ISSN: 0021-9258.
AU Wang Jian Feng; Zhang Xuefeng; Groopman Jerome E
AN 2004305796 MEDLINE

L62 ANSWER 79 OF 280 MEDLINE on STN DUPLICATE 29
TI Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
SO Journal of biological chemistry, (2004 May 14) 279 (20) 21658-65. Electronic Publication: 2004-03-09. Journal code: 2985121R. ISSN: 0021-9258.
AU Podar Klaus; Mostoslavsky Gustavo; Sattler Martin; Tai Yu-Tzu; Hayashi Toshiaki; Catley Laurence P; Hideshima Teru; Mulligan Richard C; Chauhan Dharminder; Anderson Kenneth C
AN 2004234576 MEDLINE

L62 ANSWER 80 OF 280 MEDLINE on STN
TI Role of vav1- and src-related tyrosine kinases in macrophage activation by CpG DNA.
SO Journal of biological chemistry, (2004 Apr 2) 279 (14) 13809-16. Electronic Publication: 2004-01-28. Journal code: 2985121R. ISSN: 0021-9258.
AU Stovall Stephanie H; Yi Ae-Kyung; Meals Elizabeth A; Talati Ajay J; Godambe Sandip A; English B Keith
AN 2004154652 MEDLINE

L62 ANSWER 81 OF 280 MEDLINE on STN DUPLICATE 30
TI Role of protein tyrosine kinase p53/56lyn in diminished lipopolysaccharide priming of formylmethionylleucyl- phenylalanine-induced superoxide production in human newborn neutrophils.
SO Infection and immunity, (2004 Nov) 72 (11) 6455-62. Journal code: 0246127. ISSN: 0019-9567.
AU Yan Sen Rong; Byers David M; Bortolussi Robert
AN 2004530831 MEDLINE

L62 ANSWER 82 OF 280 EMBASE on STN
TI PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells.
SO Journal of Cell Science, (1 Dec 2004) Vol. 117, No. 25, pp. 6085-6094. Refs: 59 ISSN: 0021-9533 CODEN: JNCSAI
AU Obara Y.; Labudda K.; Dillon T.J.; Stork P.J.S.
AN 2005038135 EMBASE

L62 ANSWER 83 OF 280 MEDLINE on STN DUPLICATE 31
TI Regulation of cell motility by tyrosine phosphorylated villin.
SO Molecular biology of the cell, (2004 Nov) 15 (11) 4807-17. Electronic Publication: 2004-09-01.

Journal code: 9201390. ISSN: 1059-1524.
AU Tomar Alok; Wang Yaohong; Kumar Narendra; George Sudeep; Ceacareanu Bogdan; Hassid Aviv; Chapman Kenneth E; Aryal Ashish M; Waters Christopher M; Khurana Seema
AN 2004534327 MEDLINE

L62 ANSWER 84 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance.
SO Oncogene, (29 Apr 2004) Vol. 23, No. 20, pp. 3530-3540.
Refs: 47
ISSN: 0950-9232 CODEN: ONCNES
AU Vega M.I.; Huerta-Yepaz S.; Garban H.; Jazirehi A.; Emmanouilides C.; Bonavida B.
AN 2004224066 EMBASE

L62 ANSWER 85 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Antiproliferative effects of **Src inhibition** on medullary thyroid cancer.
SO Journal of Clinical Endocrinology and Metabolism, (2004) Vol. 89, No. 7, pp. 3503-3509.
Refs: 50
ISSN: 0021-972X CODEN: JCEMAZ
AU Liu Z.; Falola J.; Zhu X.; Gu Y.; Kim L.T.; Sarosi G.A.; Anthony T.; Nwariaku F.E.
AN 2004310969 EMBASE

L62 ANSWER 86 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Metabotropic glutamate receptor-mediated depression of the slow afterhyperpolarization is gated by tyrosine phosphatases in hippocampal CA1 pyramidal neurons.
SO Journal of Neurophysiology, (2004) Vol. 92, No. 5, pp. 2811-2819.
Refs: 55
ISSN: 0022-3077 CODEN: JONEA4
AU Ireland D.R.; Guevremont D.; Williams J.M.; Abraham W.C.
AN 2005113828 EMBASE

L62 ANSWER 87 OF 280 MEDLINE on STN DUPLICATE 32
TI Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
SO Molecular endocrinology (Baltimore, Md.), (2004 Nov) 18 (11) 2700-13.
Electronic Publication: 2004-08-05.
Journal code: 8801431. ISSN: 0888-8809.
AU Gaben Anne-Marie; Saucier Cecile; Bedin Monique; Redeuilh Gerard; Mester Jan
AN 2004536836 MEDLINE

L62 ANSWER 88 OF 280 HCAPLUS COPYRIGHT 2005 ACS on STN
TI A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2613-2616
CODEN: BMCLE8; ISSN: 0960-894X
AU Borhani, David W.; Calderwood, David J.; Friedman, Michael M.; Hirst, Gavin C.; Li, Biqin; Leung, Adelaine K. W.; McRae, Brad; Ratnofsky, Sheldon; Ritter, Kurt; Waegell, Wendy
AN 2004:346273 HCAPLUS
DN 141:81914

L62 ANSWER 89 OF 280 MEDLINE on STN DUPLICATE 33
TI New **pyrazolo**[3,4-d]**pyrimidines** endowed with A431

antiproliferative activity and **inhibitory** properties of **Src** phosphorylation.
SO Bioorganic & medicinal chemistry letters, (2004 May 17) 14 (10) 2511-7. Journal code: 9107377. ISSN: 0960-894X.
AU Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Mosti L; Menozzi G; Carraro F; Naldini A; Bernini C; Manetti F; Botta M
AN 2004212341 MEDLINE

L62 ANSWER 90 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Oncogenic Raf-1 regulates epithelial to mesenchymal transition via distinct signal transduction pathways in an immortalized mouse hepatic cell line.
SO Carcinogenesis, (2004) Vol. 25, No. 12, pp. 2385-2395.
Refs: 46
ISSN: 0143-3334 CODEN: CRNGDP
AU Lan M.; Kojima T.; Osanai M.; Chiba H.; Sawada N.
AN 2004528473 EMBASE

L62 ANSWER 91 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI Coordinate signaling by Src and p38 kinases in the induction of cortical cataracts.
SO Investigative Ophthalmology and Visual Science, (2004) Vol. 45, No. 7, pp. 2314-2323.
Refs: 76
ISSN: 0146-0404 CODEN: IOVSDA
AU Zhou J.; Menko A.S.
AN 2004299053 EMBASE

L62 ANSWER 92 OF 280 MEDLINE on STN DUPLICATE 34
TI **Inhibition** of **SRC** tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Apr 1) 10 (7) 2307-18. Journal code: 9502500. ISSN: 1078-0432.
AU Duxbury Mark S; Ito Hiromichi; Zinner Michael J; Ashley Stanley W; Whang Edward E
AN 2004178445 MEDLINE

L62 ANSWER 93 OF 280 HCAPLUS COPYRIGHT 2005 ACS on STN
TI Kinase inhibitors and cytotoxic drug resistance
SO Clinical Cancer Research (2004), 10(7), 2205-2207
CODEN: CCREF4; ISSN: 1078-0432
AU Grant, Steven; Dent, Paul
AN 2004:290896 HCAPLUS
DN 141:306711

L62 ANSWER 94 OF 280 MEDLINE on STN
TI Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.
SO Blood, (2004 Sep 15) 104 (6) 1745-52. Electronic Publication: 2004-06-08. Journal code: 7603509. ISSN: 0006-4971.
AU Hardy Adam R; Jones Matthew L; Mundell Stuart J; Poole Alastair W
AN 2004436241 MEDLINE

L62 ANSWER 95 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
TI SRC: Regulation, role in human carcinogenesis and pharmacological inhibitors.
SO Current Pharmaceutical Design, (2004) Vol. 10, No. 15, pp. 1745-1756.
Refs: 261
ISSN: 1381-6128 CODEN: CPDEFP
AU Tsygankov A.Y.; Shore S.K.

AN 2004219492 EMBASE

L62 ANSWER 96 OF 280 MEDLINE on STN
TI Hydrogen peroxide generation induces pp60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry.
SO Journal of biological chemistry, (2004 Jan 16) 279 (3) 1665-75. Electronic Publication: 2003-10-27. Journal code: 2985121R. ISSN: 0021-9258.
AU Rosado Juan A; Redondo Pedro C; Salido Gines M; Gomez-Arteta Emilio; Sage Stewart O; Pariente Jose A
AN 2004018590 MEDLINE

L62 ANSWER 97 OF 280 MEDLINE on STN DUPLICATE 35
TI Combination of an **SRC** kinase **inhibitor** with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
SO Clinical cancer research : an official journal of the American Association for Cancer Research, (2004 Feb 15) 10 (4) 1545-55. Journal code: 9502500. ISSN: 1078-0432.
AU Boyd Douglas D; Wang Heng; Avila Hector; Parikh Nila U; Kessler Horst; Magdolen Victor; Gallick Gary E
AN 2004088380 MEDLINE

L62 ANSWER 98 OF 280 MEDLINE on STN
TI Tyrosine phosphorylation of NOS3 in a breast cancer cell line and Src-transformed cells.
SO Oncology reports, (2004 May) 11 (5) 1059-62. Journal code: 9422756. ISSN: 1021-335X.
AU Takenouchi Yasushi; Oo Myat Lin; Senga Takeshi; Watanabe Yasuo; Machida Kazuya; Miyazaki Kou; Nimura Yuji; Hamaguchi Michinari
AN 2004175240 MEDLINE

L62 ANSWER 99 OF 280 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes.
SO Journal of Molecular and Cellular Cardiology, (November 2004) Vol. 37, No. 5, pp. 989-999. print. ISSN: 0022-2828 (ISSN print).
AU Germack, Renee [Reprint Author]; Griffin, Martin; Dickenson, John M.
AN 2005:171542 BIOSIS

L62 ANSWER 100 OF 280 MEDLINE on STN DUPLICATE 36
TI **Src** family kinase **inhibitor** PP1 reduces secondary damage after spinal cord compression in rats.
SO Journal of neurotrauma, (2004 Jul) 21 (7) 923-31. Journal code: 8811626. ISSN: 0897-7151.
AU Akiyama Chihiro; Yuguchi Takamichi; Nishio Masami; Tomishima Takahiro; Fujinaka Toshiyuki; Taniguchi Masaaki; Nakajima Yoshikazu; Kohmura Eiji; Yoshimine Toshiki
AN 2004404797 MEDLINE

=> d ab 89,95

L62 ANSWER 89 OF 280 MEDLINE on STN DUPLICATE 33
AB New 4-**aminopyrazolo**[3,4-d]**pyrimidines** bearing various substituents at the position 1 and 6, were synthesized. The new compounds showed antiproliferative activity toward A431 cells, were found to be **inhibitors** of **Src** phosphorylation, and induced apoptotic cell death. In particular, 2h was a better **inhibitor** of **Src** phosphorylation than the reference compound PP2.

L62 ANSWER 95 OF 280 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

AB The cellular signaling machinery is a complex network of cross-talking proteins that enables dynamic communication between upstream causal factors and downstream effectors. Non-receptor tyrosine kinases, including Src, are the intermediates of signal transfer, controlling pathways as diverse as cell growth, death, differentiation, migration, and genome maintenance. When expressed as viral genes these proteins are potent carcinogens. Furthermore, analogous genetic alterations are observed, albeit not frequently, in human tumors. In a variety of tumors including those derived from the colon and breast, Src is either over expressed or constitutively active in a large percentage of patients. Increased expression or activity of Src correlates with the stage and metastatic potential of some neoplasia. The detailed knowledge of Src activation facilitates rational design of drugs that potentially interfere with either binding of ATP or substrate peptides. Several existing inhibitors are available as lead compounds for further development of **Src inhibitors.** .COPYRGT. 2004 Bentham Science Publishers Ltd.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	291.11	291.32

STN INTERNATIONAL LOGOFF AT 11:45:43 ON 09 AUG 2005